{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:29:33Z","timestamp":1776277773287,"version":"3.50.1"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1001\/jamadermatol.2020.3384","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T16:34:50Z","timestamp":1605112490000},"page":"25","source":"Crossref","is-referenced-by-count":15,"title":["Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia"],"prefix":"10.1001","volume":"157","author":[{"given":"Roger S.","family":"Ho","sequence":"first","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"7","key":"ded200016r2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/phar.1612","article-title":"Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study.","volume":"35","author":"Ali","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"6","key":"ded200016r4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamadermatol.2015.36","article-title":"Adverse event reporting in clinical trials of finasteride for androgenic alopecia: a meta-analysis.","volume":"151","author":"Belknap","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"10","key":"ded200016r5","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/0895-4356(92)90158-J","article-title":"Serum sickness-like reactions to cefaclor.","volume":"45","author":"Stricker","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"ded200016r6","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.2337\/dc10-2412","article-title":"Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.","volume":"34","author":"Piccinni","year":"2011","journal-title":"Diabetes Care"},{"issue":"5","key":"ded200016r7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/bjd.2016.175.issue-5","article-title":"Risk assessment of drug-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a disproportionality analysis using the French Pharmacovigilance Database.","volume":"175","author":"Agier","year":"2016","journal-title":"Br J Dermatol"},{"issue":"7","key":"ded200016r8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14740338.2019.1619693","article-title":"Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.","volume":"18","author":"Aggarwal","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"ded200016r9","article-title":"Investigation of suicidality and psychological adverse events in patients treated with finasteride.","author":"Nguyen","journal-title":"JAMA Dermatol"},{"issue":"6","key":"ded200016r10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"ded200016r11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.pbb.2006.06.016","article-title":"Neurosteroids, neuroactive steroids, and symptoms of affective disorders.","volume":"84","author":"Dubrovsky","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"issue":"9","key":"ded200016r12","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects.","volume":"73","author":"Irwig","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"ded200016r1","unstructured":"Propecia. Letters, reviews, labels, patient package insert. Merck; 1997. Accessed October 7, 2020. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020788"},{"key":"ded200016r3","unstructured":"The Post-Finasteride Syndrome Foundation. About the Post-Finasteride Syndrome Foundation. Accessed October 7, 2020. https:\/\/www.pfsfoundation.org\/about-post-finasteride-syndrome-foundation\/"},{"key":"ded200016r13","unstructured":"Google Trends. Post-finasteride [2004-present]. Accessed October 7, 2020. https:\/\/trends.google.com\/trends\/explore?date=all&geo=US&q=post-finasteride"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2772815\/jamadermatology_ho_2020_ed_200016_1610466896.89698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T16:01:58Z","timestamp":1611158518000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2772815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.3384","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}